

ACTISORB® Evidence Highlights

The effect of ACTISORB® on chronic wounds with no clinical signs of infection

High levels of bacteria can interfere with wound repair mechanisms, thereby delaying healing. Controlling or preventing the presence of bacteria becoming an infection could therefore reduce healing times. The study aimed to explore the effect of ACTISORB® activated charcoal silver dressing (intervention) with cleansing and debridement (control) in **reducing the level of bacteria in chronic wounds with no signs of local infection.**

Patients were randomly assigned to the intervention or control group and monitored for two weeks. Samples were taken for bacterial cultivation and status.

After two weeks of treatment **the group treated with ACTISORB® had no colonised wounds compared to 75% of the control group.**




Fig 1 The number of infected wounds after two weeks of treatment with either ACTISORB® (The intervention) or Cleansing and debridement (the control)

This study indicates that ACTISORB® has the potential to eliminate bacteria, control infection and reduce healing times.

Soriano et al. Journal of Wound care. Vol 13. No 10. November 2004


A case study to demonstrate use of a charcoal dressing with silver on an MRSA-infected wound

The case study shows the use of ACTISORB® activated charcoal dressing to treat a wound infected with MRSA. The complex nature of the patient's medical history indicated that his wound would be a major challenge to heal, being a type 1 diabetic, having undergone a kidney transplant, and being immuno-suppressed.

The wound was cleaned and then treated by using NA® non-adherent dressing as a contact layer, then packing the cavity wound with ACTISORB® activated charcoal silver dressing.

Over the course of the treatment steady progress was noted; including reduced pus levels, reflecting a reduction in the bacterial bioburden.

As the infection level decreased, the wound was able to progress from the inflammatory phase. **Wound swabs (taken as per hospital protocol as part of the screening process for MRSA linked to the treatment policy of the trust) were reported as negative 2 weeks after commencing use of ACTISORB® – and remained negative on subsequent swabs.**



Initial assessment of the wound



Complete closure of the wound following treatment

Implementation of this dressing regime allowed the wound to pass through the normal stages of wound healing without the compromise of infection.

Jackson, L. Use of a charcoal dressing with silver on an MRSA infected wound. Br. J. Community Nursing 2001, 6(12) suppl. 2: 19-26.

Let's Talk...

To learn more about the benefits of **ACTISORB®**, contact your Systagenix representative or visit ww.systagenix.com